Company Short-Term Debt: luciddx.com (LUCD)

Public company logo of Lucid Diagnostics (LUCD)

Lucid Diagnostics Inc. (LUCD) protects its business through patents and FDA approval, while integration into medical protocols and insurance reimbursement creates a powerful market barrier. Physician trust is based on the effectiveness of the painless EsoGuard method for detecting precancerous conditions. This chart of market value demonstrates that the specific short-term debt metric stands at 0.03, confirming the company's financial stability within the laboratory diagnostics sector.

LUCD (Lucid Diagnostics) Company Short-Term Debts history from 07/04/2022 to 10/29/2026

Analytical breakdowns and data insights for company Lucid Diagnostics, Inc (LUCD)

- stock price and consensus target price:
Stock Price Lucid Diagnostics|LUCD - Analyst Consensus Forecast
- company stock exchange capitalization indicators:
Market Value Lucid Diagnostics Inc.|LUCD - Business Value
- shareholders' equity book value data:
Book Value per Share Lucid Diagnostics|LUCD - Book Capitalization|Market Value to Book Value Ratio luciddx.com|LUCD - Aggregate Company Assets
- debt burden and liquidity indicators:
Total Debt to Equity Ratio Lucid Diagnostics Inc.|LUCD - Long-Term Liabilities to Capital|Short-Term Debt to Equity Lucid Diagnostics Inc.|LUCD - Company Total Debt Obligations|Debts to Book Capitalization Lucid Diagnostics Inc.|LUCD - Long-Term Debt Volume|Company Short-Term Debt Lucid Diagnostics
Fundamental company analysis:Lucid Diagnostics (LUCD)
Flagship merchandise of Lucid Diagnostics Inc.

The development of esophageal cancer diagnostics requires significant investments in marketing and staff training from Lucid Diagnostics Inc. (LUCD). This indicator aggregates all credit obligations with a maturity of up to one year. It is critical for investors to compare this volume with liquid assets to assess the risk of a cash flow gap. Rising debt coupled with low insurance payouts signals financial instability. The dynamics of short-term financial debt reflect the current solvency of the company.

Competitors of Lucid Diagnostics Inc.

Agilent - Company Short-Term Debts|DGX - Company Short-Term Debts|Illumina Corp (ILMN) - Company Short-Term Debt|Company Short-Term Indebtedness EXAS|RVTY (Revvity, Inc.) - Company Short-Term Debts|Company Short-Term Debts bio-rad.com|Company Short-Term Debt Anbio (NNNN)|Company Short-Term Debt SHC (Sotera Health Corp)|QuidelOrtho Corp - Company Current Liabilities|OPKO Health Corp. (OPK) - Short-Term Debt|CDNA - Company Short-Term Debt|Short-Term Debt Volume maravai.com MRVI|FLGT: Company Short-Term Debts|LAB - Short-Term Debt Volume|Company Short-Term Debt Cytek Bio|OraSure Corp (OSUR) - Short-Term Debt Volume|Company Short-Term Debt Exagen Inc. (XGN)|Company Short-Term Debt MDXH (mdxhealth.com)|Prenetics - Company Current Liabilities|Company Short-Term Debts Insight Molecular Diagnostics, Inc. IMDX|Trinity Biotech Corp - Company Short-Term Debts|ProPhase Labs Corp (PRPH) - Company Current Liabilities|AIMD: Company Short-Term Debts|CODX - Short-Term Debt Volume|HSCS (HeartSciences) - Company Short-Term Debts|Company Short-Term Indebtedness BMRA (Biomerica Inc.)|Company Current Liabilities CDIO (Cardio Diagnostics)|VRAX (Virax Biolabs Corp) - Company Short-Term Loans and Borrowings|Company Short-Term Debts BJDX (Bluejay Diagnostics)|AWH: Company Short-Term Indebtedness|Accelerate Diagnostics, Inc. - Company Short-Term Debts|Short-Term Debt Volume CENTOGENE N.V. CNTG|ENZ: Company Short-Term Debts|Fresh2 Group (FRES) - Company Short-Term Debts|GENE (Genetic Technologies Ltd) - Company Short-Term Debts|ME - Short-Term Indebtedness|Company Short-Term Debt Psychemedics Corporation (PMD)